New study aims to Fine-Tune antifungal dosing for ICU patients on plasma exchange
NCT ID NCT07532850
First seen Apr 16, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study looks at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill adults with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange affects drug levels, so doctors can give the right dose for each patient. The study does not test a new treatment but gathers information to improve personalized care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.